The FDA has granted a priority review for Millennium's Velcade for relapsed mantle cell lymphoma. Velcade is currently approved for patients with multiple myeloma who have failed at least one standard therapy. "Receiving priority review is a significant step forward in accelerating and expanding the potential of Velcade in cancers beyond multiple myeloma," said Deborah Dunsire, Millennium's president and CEO.
- here's the UPI report on Velcade